{"doi":"10.17615/ne0v-qz87","title":"Unknown","abstract":null,"journal":null,"year":null,"id":625741,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in naïve and dengue exposed individuals","abstract":"Sanofi Pasteur has developed a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) that is currently approved for use in several countries. In clinical trials, CYD-TDV was efficacious at reducing laboratory-confirmed cases of dengue disease. Efficacy varied by dengue virus (DENV) serotype and pre-vaccination dengue immune status. We compared the properties of antibodies in naïve and DENV exposed individuals who received CYD-TDV. We depleted specific populations of DENV-reactive antibodies from immune sera to estimate the contribution of serotype-cross reactive and type-specific antibodies to neutralization. Subjects with no pre-existing immunity to DENV developed neutralizing antibodies to all 4 serotypes of DENV. Further analysis demonstrated that DENV4 was mainly neutralized by type-specific antibodies whereas DENV1, 2 and 3 were mainly neutralized by serotype cross-reactive antibodies. When subjects who had pre-existing immunity to DENV were vaccinated, they developed higher levels of neutralizing antibodies compared to naïve subjects who were vaccinated. In pre-immune subjects CYD-TDV boosted cross-reactive neutralizing antibodies, while maintaining type-specific neutralizing antibodies acquired before vaccination. Our results demonstrate that the quality of neutralizing antibodies induced by CYD-TDV varies depending on DENV serotype and previous immune status. We discuss the implications of these results for understanding vaccine efficacy.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19910364","pmcid":null,"openalex_id":"https://openalex.org/W4299784416","authors":[],"funders":[],"total_grants":0,"fwci":0.0,"citation_percentile":0.40720069,"influential_citations":0,"citation_trend":[],"oa_status":"green","license":"http://rightsstatements.org/vocab/InC/1.0/","oa_locations":[{"url":"https://doi.org/10.17615/ne0v-qz87","host_type":"repository"}],"fields_of_study":["Mosquito-borne diseases and control","Viral Infections and Outbreaks Research","Viral Infections and Vectors"],"mesh_terms":[],"keywords":["Dengue fever","Dengue vaccine","Virology","Yellow fever vaccine","Yellow fever","Dengue virus","Antibody","Medicine","Immunology","Virus"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T07:44:03.324452Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}